Sucampo present lubiprostone phase 3 trial data in Japanese CIC in DDW 2011 Sucampo Pharmaceuticals.

In a evaluation of time to initial SBM pursuing initiation of therapy, the lubiprostone group had a statistically significant increase in the proportion of sufferers reporting first SBMs within a day when compared with placebo. Patients’ global assessment of treatment effectiveness was considerably improved for lubiprostone-treated sufferers vs. Those treated with placebo over the duration of the study. In the 48 week open-label, long-term basic safety trial: Throughout the 48-week treatment period, patients reported a statistically significant elevated average number of every week SBMs than were observed at baseline. As compared to baseline evaluation of quality of life measures, lubiprostone treatment resulted in better SF-36 and IBS-QOL scores overall. Specifically, lubiprostone-treated patients reported statistically significant improvements in the following domains of the SF-36 questionnaire at Week 48: physical function , bodily discomfort , general health , and emotional part ; lubiprostone obtained considerably in each domain within the IBS-QOL questionnaire.For more information about how psychological accessories create self-sabotage, watch this simple, enlightening and free video. If you like this article, after that like my Facebook web page to maintain with all my writing. Source: the author:Watch the free video The AHA! Process: An End to Self-Sabotage and discover the lost keys to personal transformation and emotional well-being which have been suppressed by mainstream mental health for decades. The info in this video offers been called the missing link in mental health and personal development.